Apimeds Pharmaceuticals US, Inc. (APUS)
NYSEAMERICAN: APUS · Real-Time Price · USD
1.906
+0.046 (2.47%)
Sep 5, 2025, 4:00 PM - Market closed

APUS Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
2.951.280.650.270.53
Research & Development
0.65-0.10.370.49
Operating Expenses
3.61.280.750.641.02
Operating Income
-3.6-1.28-0.75-0.64-1.02
Interest Expense
-0.13-0.12-0.04-0.03-0.01
Interest & Investment Income
0.0200.01--
Pretax Income
-3.71-1.39-0.78-0.67-1.03
Net Income
-3.71-1.39-0.78-0.67-1.03
Net Income to Common
-3.71-1.39-0.78-0.67-1.03
Shares Outstanding (Basic)
98544
Shares Outstanding (Diluted)
98544
Shares Change (YoY)
28.67%71.89%19.55%--
EPS (Basic)
-0.43-0.18-0.17-0.17-0.27
EPS (Diluted)
-0.43-0.18-0.17-0.17-0.27
EBIT
-3.6-1.28-0.75-0.64-1.02
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q